OBJECTIVE
People with Parkinson's disease (PD) who carry a pathogenic GBA1 variant (PDGBA1) are at higher risk of cognitive impairment than those without the variant (PDGBA1_wildtype). To date, little is known about the pattern and evolution of cognitive decline in PDGBA1. This multicenter study characterized the cogni...
Merle Bode, C. Pauly, S. Jónsdóttir et al.· Annals of Neurology· 0 citations
Background: Lysosomal dysfunction has been implicated in Parkinson's disease (PD) pathogenesis. However, lysosomal polygenic risk scores (lyso-PRS) have not been evaluated extensively in PD across populations. Objectives: (1) Evaluation of lyso-PRS (lyso-PRS) performance for PD risk across populations; (2) Comparison o...
W. Sun, K. Brockmann, I. Wurster et al.· medRxiv· 0 citations
Digital health technology (DHT) enables to detect and quantify charateristics motor dysfunction in Parkinsons disease (PD). However, the understanding of the relationship between dopaminergic nigrostriatal denervation and quantitative composite digital motor scores (DMS) captured by DHT remains largely limited to date....
B. Roeben, D. Blum, B. Montes et al.· medRxiv· 0 citations
CSF TIMP2 levels primarily reflect ageing-related processes associated with neurodegeneration rather than disease-specific effects, and support a role of extracellular matrix-related ageing mechanisms in PD and related disorders.
M. Zimmermann, Madeleine Fandrich, C. Schulte et al.· GeroScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.